Abstract
Background: The reliable detection of myositis-specific autoantibodies (MSA) provides valuable clinical information regarding prognosis, clinical progression and diagnostic confirmation.
Objectives: To evaluate the reliability of a commercial ELISA immunoassay in detecting myositis-specific autoantibodies in comparison to immunoprecipitation as the reference standard.
Methods: Serum samples were chosen from a biobank of more than 3000 samples. Samples with a confirmed MSA on Immunoprecipitation (n=116) were evaluated in duplicate by ELISA to detect Mi2, MDA5, Jo1, EJ, KS, PL-7 and PL-12 (Medical & Biological Laboratories Co. Ltd, Nagoya, Aichi, Japan). Healthy control samples (n=246) confirmed autoantibody negative by immunoprecipitation were similarly assessed.
Results: There was a very good agreement between ELISA and immunoprecipitation for serum samples containing anti-Mi2, MDA5, Jo1, EJ, KS and PL-7 and PL-12 auto-antibodies. Cohen's κ values ranged from 0.86-1 for the measured autoantibodies on ELISA.
Conclusion: ELISA was an accurate method for detecting anti-synthetase, anti-Mi2 and anti-MDA5 autoantibodies.
| Original language | English |
|---|---|
| Article number | 975939 |
| Journal | Frontiers in Immunology |
| Volume | 13 |
| DOIs | |
| Publication status | Published - 8 Sept 2022 |
Bibliographical note
Funding Information:This work was supported by funding from CureJM and the Bath Institute of Rheumatic Diseases. ELISA kits were provided by MBL. AL’s position at the Royal National Hospital of Rheumatic Diseases is part-funded by the Ken Muirden Fellowship from Arthritis Australia.
Keywords
- ELISA - enzyme-linked immunosorbent assay
- diagnostic accuracy
- diagnostic test
- immunoprecipitation (IP)
- inflammatory myositis
- myositis autoantibody
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology